MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 125 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
Reply to C. Parker et al
Ian M. Thompson
2009· article· fr· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affaboutunlabeled
Follow-up of long-term young breast cancer survivors.
Corinne Daly, Elisabeth M. Del Giudice, Rinku Sutradhar, Lawrence Paszat, D. H. C. Wilton, Linda Rabeneck +1 more
2012· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Efficacy of the novel treatments of BCC with bone metastasis.
Mohammad Ali Esmaeil Pour, Mahsa Mohebtash, Ali Amin, Azadeh Khayyat, Amir-Reza Khalili-Toosi, S Mousavi +2 more
2022· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.
Edoardo Francini, Francesca Montagnani, Pier Vitale Nuzzo, Miguel González-Vélez, Nimira Alimohamed, Antonio Cigliola +14 more
2020· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affaboutunlabeled
Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.
Anil A. Joy, Shailendra Verma, Louise Provencher, Kathy Puyana Theall, Dongrui R. Lu, Florence Dequen +1 more
2017· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About